Prevalence and Characteristics of Deoxycholate and Liposomal Amphotericin B Adverse Reactions in a Third‐Level Care Hospital: A Retrospective Observational Study.
Background: We aimed to establish the prevalence of adverse reactions associated with the use of deoxycholate and/or liposomal amphotericin B and to determine adherence to World Health Organization (WHO) recommendations to minimize the risk of toxicity. Methods: Clinical data were collected from rec...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 2026; pp. 1 - 8 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
6/21/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194753713&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194753713 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: 6/21/2026 vid: 2026 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 194753713 194753713 194753713 10.1155/jcpt/2980716 194753713 ppf: 1 ppct: 7 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Prevalence and Characteristics of Deoxycholate and Liposomal Amphotericin B Adverse Reactions in a Third‐Level Care Hospital: A Retrospective Observational Study. aug: au: Vargas, Thalia Berenice Jacobo Portugal, Miriam del Carmen Carrasco Saldaña, Renata Báez Ganen, Odalis Rodríguez Murrieta, Francisco Javier Flores Topete, Victor Hugo Ahumada Barrientos, Ricardo Stanley Vega Degu, Amsalu affil: Clinical and Experimental Pharmacology Laboratory,, National Institute of Respiratory Diseases,, Mexico City, Mexico, iner.salud.gob.mx sug: subj: Tertiary Health Care Mexico Bile Acids and Salts Adverse Effects Amphotericin B Adverse Effects Drug Combinations Adverse Effects Adverse Drug Event Epidemiology Adverse Drug Event Risk Factors Adverse Drug Event Prevention and Control World Health Organization Guideline Adherence Human Mexico Male Female Adult Middle Age Retrospective Design Record Review Prospective Studies Nonexperimental Studies Fluid Therapy Electrolytes Therapeutic Use Hypokalemia Chemically Induced Hypomagnesemia Chemically Induced Kidney Failure, Acute Chemically Induced Anemia Chemically Induced Thrombocytopenia Chemically Induced Neutropenia Chemically Induced Descriptive Statistics Bivariate Statistics Chi Square Test Data Analysis Software Treatment Duration Hospital Mortality Adult: 19-44 years Middle Aged: 45-64 years Male Female ab: Background: We aimed to establish the prevalence of adverse reactions associated with the use of deoxycholate and/or liposomal amphotericin B and to determine adherence to World Health Organization (WHO) recommendations to minimize the risk of toxicity. Methods: Clinical data were collected from records of 143 patients over 18 years of age who were under treatment with amphotericin B (deoxycholate and/or liposomal) for at least 5 days from January 2016 to March 2019 at National Institute of Respiratory Diseases "Ismael Cosío Villegas" in Mexico City. We used MeSH terms to name each formulation of amphotericin B, adverse reactions, and diagnoses. Definitions and classification of the adverse reactions were made in accordance with the Common Terminology Criteria for Adverse Events Version 5.0 and other bibliographic references. Preventability assessment was evaluated using the Schumock and Thornton scale. To determine adherence to WHO recommendations, we evaluated intravenous preemptive hydration, electrolyte supplementation, and laboratory test monitoring. Results: 105 patients (73.4%) were exposed to deoxycholate amphotericin B, 25 patients (17.5%) to liposomal amphotericin B, and 13 patients (9.1%) to both amphotericin B types. Hypokalemia was the most common adverse reaction (76.2%), followed by hypomagnesemia (47.6%), acute kidney injury (40.6%), infusion reactions (33.6%), anemia (20.3%), thrombocytopenia (7%), and neutropenia (4.9%). Electrolyte supplementation was the WHO recommendation that was less performed (28%), while preemptive hydration and laboratory test monitoring were well applied (82.5% and 84.6%). Conclusion: This study highlights the need to adhere to amphotericin B toxicity prevention recommendations as some of the most common adverse reactions are mostly preventable. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|